newborn screening in pakistan when & how ? col zeeshan ahmed fcps(pediatrics),fcps(neonatology)...
TRANSCRIPT
NEWBORN SCREENING IN PAKISTAN
When & How ?Col Zeeshan Ahmed
FCPS(Pediatrics),FCPS(Neonatology)Head Of NICU
Military Hospital Rwp.
CAN WE MAKE A DIFFERENCE?
Mission of Newborn Screening: AAP
“Newborn screening…aimed at the early identification of conditions for which early and timely interventions can lead to the elimination or reduction of associated mortality, morbidity, and disabilities.”
Mission of Newborn Screening: AAP
“Newborn screening…aimed at the early identification of conditions for which early and timely interventions can lead to the elimination or reduction of associated mortality, morbidity, and disabilities.”
Newborn Screening
The term is used to refer to two programs that may or may not have linkages:
1. Traditional biochemical screening for inherited conditions (metabolic, endocrine, hematological, etc.)
2. Screening for congenital hearing loss
In this presentation, “newborn screening” will refer to the traditional heelstick biochemical testing program.
What is Newborn Screening? • An essential public health program that prevents
catastrophic health consequences through early detection, diagnosis and treatment.
• A complex system of testing, evaluation, and treatment that involves families, laboratory personnel, administrative and follow-up personnel, primary and specialty health care professionals, policy makers, sources of payments, manufacturers, and other interested persons or groups.
Newborn Screening• Newborn screening developed worldwide from a keen
interest and understanding of Inborn Errors of Metabolism- a term introduced by Garrod in 1908
• Newborn Screening has focused historically on the identification of conditions that adversely affect the CNS
• Increasingly, conditions involving other areas, such as the immune and cardiac systems have been recommended for the newborn screening panel
• Newborn screening has been driven to a considerable extent by available technology, and increasingly by better understanding of conditions as well as by new diagnostic technologies and treatments.
THE US EXPERIENCE
Newborn Screening for Genetic Diseases in the United States
• Over 4 million infants are screened each year• Newborn screening is by far the most commonly performed testing for genetic
diseases in the United States
Brief Review:Newborn Screening History
1960s Guthrie developed
filter paper test for PKU. (Identified newborns with PKU whose diet could be modified thus preventing mental retardation.)
Bob Guthrie Guthrie - 1961
Disorders Included Under Current Mission
PKUPKU
19631963 19871987
Sickle Cell Disease
Sickle Cell Disease
Congenital Hypothyroidism
Congenital Hypothyroidism
Late 1970sLate
1970s
Cystic FibrosisCystic
Fibrosis
20032003
Tandem Mass Spec Disorders
Tandem Mass Spec Disorders
20042004 20??20??
??
Selection Criteria For ScreeningPanel
Availability of treatment Cost of treatment Efficacy of treatment Benefits of early intervention Benefits of early identification Acute management Simplicity of therapy
Incidence of conditions Identifiable at birth Burden of disease Mortality/ Morbidity
prevention
Availability of test Test characteristics Diagnostic confirmation
13
Uniform Screening Panel29 Primary (Core) Conditions
• All result in serious medical complications (e.g., developmental delay) and/or death if not recognized early
• All children with these conditions benefit from early diagnosis and treatment
14
Expanded NBS – 29 conditions• 20 inborn errors of metabolism
– 9 organic acid disorders– 5 fatty acid oxidation disorders– 6 amino acid disorders
• 3 hemoglobinopathies– Sickle cell and related disorders
• 2 endocrine disorders– Congenital Hypothyroidism– CAH
• 3 other metabolic disorders– Biotinidase deficiency– Galactosemia– Cystic Fibrosis
• 1 hearing loss
3 Disorders (1)
More than 8 Disorders (32) [More than 30 Disorders (15)]
7 Disorders (4)
6 Disorders (4)
5 Disorders (2)
4 Disorders (6)
8 Disorders (2)U.S. Newborn Screening
Mandated Disorders – Nov. 2004 (Note: Other disorders may be offered but are not mandated and some mandated may yet not
be implemented)
>30
>30 26>30
>30
9>30
>30
>30
>30>30
26
40
14
29
9
9
>3029
19
12
9
10
21
>30
13 10
>30>30
27
DC
>30
>30
Disorders Mandated in United StatesNovember 2004
35(4)
22 (1)2
8 (4)
51 51 49 (2) 51
40 (1)37 (4)
35 (2) 34 (5)
0
10
20
30
40
50
60
Phe
nylk
eton
uria
Hyp
othy
roid
ism
Cla
ssic
al G
alac
tose
mia
Hem
oglo
bino
path
ies
Con
geni
tal A
dren
al H
yper
plas
ia
Map
le S
yrup
Uri
ne D
isea
se
Bio
tinid
ase
Def
icie
ncy
Hom
ocys
tinur
iaC
ystic
Fib
rosi
sTo
xopl
asm
osis
G6P
D D
efic
ienc
y
HIV
MC
AD
D
Optional or Pilot ( )
Mandated
Burden of the Core Panel Conditions in the U.S.
• All conditions are rare• Over 4 million babies screened annually
• Estimated annual number confirmed (most common)– Hearing loss: 5,064– Primary congenital hypothyroidism: 2,156– Sickle cell disease: 1,775– Cystic fibrosis: 1,248– Medium-chain acyl-CoA dehydrogenase deficiency: 239
• A total of about 12,500 infants are diagnosed with the core conditions and treated each year in the US with the current newborn screening panel
18
Burden of the Core Panel Conditions in the US
• Untreated persons suffer enormous burdens– Persons with phenylketonuria have relatively
normal lifespan• Untreated: IQ that are under 20 • Identified and Treated: Normal IQ
• Persons with medium-chain acyl-CoA dehydrogenase deficiency, the most common disorder of fatty acid oxidation, are at substantial risk for sudden death
IT’S NOT JUST THE TEST!
Screening:• Sample collection
• Sample submission• Laboratory testing
Follow-up:• Obtain test results
• Get results to family • Repeat test(s) if needed
• Ensure diagnostic testing
Diagnosis:• Subspecialist Assessment• Results shared with family• Counseling if necessary
Management:• Treatment • Long-term follow-up• Specimen storage
Evaluation:• Quality assurance • Outcome evaluation• Cost effectiveness
Screening:• Sample collection
• Sample submission• Laboratory testing
Follow-up:• Obtain test results
• Get results to family • Repeat test(s) if needed
• Ensure diagnostic testing
Diagnosis:•Subspecialist Assessment•Results shared with family•Counseling if necessary
Management:•Treatment •Long-term follow-up•Specimen storage
Evaluation:• Quality assurance
• Outcome evaluation• Cost effectiveness
Education
Metabolic TeamChild Age-appropriate self-management skills
Parents Monitoring health status, teaching, advocacy
Nutritionist Nutrition therapy, feeding skills
Geneticist Medical monitoring
Social Worker Family support, counseling
Lab Laboratory monitoring
Medical Home Well child care, family support
Psychologist Developmental monitoring, counseling
PHN, others Family support in community
School Educational programs, treatment monitoring
Community Support of family and friends
Therapists (OT, PT, SLP, etc.)
Developmental monitoring, intervention
SITUATION IN OTHER DEVELOPING COUNTRIES
ASIA PACIFIC NEWBORN SCREENING COLLABORATIVE
• Two workshops - facilitate formation of the Asia Pacific Newborn Screening Collaborative.
• The 1st Workshop on Consolidating Newborn Screening Efforts in the Asia Pacific Region in Cebu, Philippines, on March 30–April 1, 2008.
• The second workshop was held on June 4–5, 2010, in Manila, Philippines.
• Workshop participants included – Key policy-makers, – Service providers, – Researchers, and – Consumer advocates
From 11 countries with 50% or less newborn screening coverage.
s. No. Country NBS INITIATED NATIONAL COVERAGE
DISORDER (s)
1. Bangladesh 1999 ≤ 5% CH
2. China 1981 59% CH, PKU
3. India 2007-8 70-86% (local) CH,CAH, G6PD DEF, CF, GAL, Various metabolic
4. Indonesia 2000 ≤ 1% CH
5. Laos 2008 7% CH
6. Mongolia 2000 6% CH,CAH
7. Pakistan 2007 ≤ 1% CH
8. Palau 2009 50% As per Phillipines panel
9. Philippines 1996 28% CH,CAH,GAL,PKU, G6PD Def
10. Sri Lanka 2005 2.8% CH
11. Vietnam 1998 7% CH,CAH, G6PD Def
BARRIERS IN COMMON
• Lack of political awareness/will (Bangladesh, India, Pakistan, Indonesia, Mongolia, Sri Lanka)
• Lack of physician awareness/ training and lack of subject specialists (Sri Lanka, Philippines, Pakistan, Mongolia, Indonesia, Bangladesh)
• Lack of consistent source of funds (Bangladesh, India, Pakistan, Philippines, Sri Lanka, Vietnam)
• Economic variations/inhibiting fee (Bangladesh, China, Indonesia, Pakistan, Philippines)
• Lack of infrastructure/labs (Indonesia, Laos, Pakistan, Sri Lanka)
• Logistic problems (Vietnam, Sri Lanka, Mongolia, Pakistan )
• Competition with other health priorities ( mentioned by India only but likely to be a universal reality)
CONCLUSIONS ON REGIONAL STATUS
• All 11 countries report progress despite significant barriers
• Infrastructure exists though limited in scope (not national)
• All programs include NBS for congenital hypothyroidism.
• China – Approx half population has access to screening for CH, PKU.
• Laws on mandated NBS exist in some countries only
THE PRESENT: WHERE DO WE STAND?
NBS: Challenges and future goals
• Barriers– Govt support uncertain– Prohibitive NBS fee ($2.35?)– Universal lack of awareness– Very limited screening coverage– Lack of standardized procedures– No consensus on treatment /followup strategies– Subject experts lacking– High home births (65%) and consanguinity (60%)– Lack of dedicated screening laboratories
THE BURDEN OF UNTREATED DISEASE
• CORE QUESTION:
The cost burden of NBS and treatment
versus
The burden of untreated preventable conditions whose cost in terms of medical services provision and loss of human resource potential is difficult to estimate
OUR HEALTH PRIORITIES
• Study: Setting Health Care Priorities in Pakistan. Khan KS. J Pak Med Assoc. 1995 Aug;45(8):222-7
OBJECTIVE:• To describe a health priority setting exercise in Pakistan
and its relevance to traditional medical care and care providers.
METHODS:• Literature search of local and regional data was performed
to identify priority health problems, those with high disease burden and with cost-effective interventions.
RESULTS
Major causes of ill-health were – Communicable ( Diarrhoea, ARI, childhood immunizable diseases,
malaria, tuberculosis)– Pregnancy related diseases.
• Factors that contributed to these disorders included – Malnutrition, – Anemia, – Poor sanitation and water supply, – Low level of education, – High fertility rates and – Poverty
• For these conditions, cost-effective interventions for prevention included– Environmental control (provision of clean water and
sanitation),– Education programmes,– Expanded programme of immunization and – Family planning
• For treatment included case management of diarrhoea, respiratory infections, tuberculosis and complications of pregnancy and childbirth.
CONCLUSION
• Priority health problems include factors outside the domain of traditional medical care.
• Their definition is important for directing policy reform, medical curricula and health research.
THE FUTURE OF NBS IN PAKISTAN:WAY FORWARD
• Balance health priorities with need for NBS• Sustained (Decades) Awareness program
targeted to health professionals, public and policy makers.
• Start with one test (e.g. CH) but establish nation wide infrastructure which will serve as springboard for future expansion
THANK YOU
THE PRESENT: WHERE DO WE STAND?